{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:46:05Z","timestamp":1790315165584,"version":"4.1.0"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Economic losses due to herpes simplex infections in low- and middle-income countries (LMICs) are unknown. We estimated economic and quality-of-life losses due to genital herpes in 2019, in 90 LMICs, and from 2020 to 2030 in 45 countries in the World Health Organization (WHO) Africa. We additionally estimated economic losses due to human immunodeficiency virus (HIV) attributable to herpes simplex virus type 2 (HSV-2) infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We estimated genital herpes-related spending on treatment, wage losses due to absenteeism, and reductions in quality of life, for individuals aged 15 to 49 years, living with genital herpes. Had HSV-2 had contributed to the transmission of HIV, we estimated the share of antiretroviral treatment costs and HIV-related wage losses in 2019 that can be attributed to incident and prevalent HSV-2 infections in 2018. For the former, we used estimates of HSV-2 incidence and prevalence from the global burden of disease (GBD) study. For the latter, we calculated population attributable fractions (PAFs), using the classic (Levin\u2019s) epidemiological formula for polytomous exposures, with relative risks (RRs) reported in literature. To extend estimates from 2020 to 2030, we modeled the transmission of HSV-2 in 45 African countries using a deterministic compartmental mathematical model, structured by age, sex, and sexual activity, which was fitted to seroprevalence gathered from a systematic review and meta-regression analysis.<\/jats:p>\n                    <jats:p>In the 90 LMICs, genital herpes contributed to US$813.5 million in treatment and productivity losses in 2019 (range: US$674.4 to US$952.2 million). Given observed care-seeking and absenteeism, losses are in the range of US$29.0 billion (US$25.6 billion to US$34.5 billion). Quality-of-life losses in the amount of 61.7 million quality-adjusted life years (QALYs) are also possible (50.4 million to 74.2 million). The mean annual cost of treatment and wage losses per infection is US$183.00 (95% CI: US$153.60 to US$212.55); the mean annual cost of quality-of-life losses is US$343.27 (95% CI: 272.41 to 414.14). If HSV-2 has fueled the transmission of HIV, then seroprevalent HSV-2 cases in 2018 can account for 33.2% of the incident HIV infections in 2019, with an associated antiretroviral therapy (ART) cost of US$186.3 million (range: US$163.6 to US$209.5 million) and 28.6% of HIV-related wage losses (US$21.9 million; range: US$19.2 to US$27.4 million). In the WHO Africa region, the 3.9 million seroprevalent genital herpes cases from 2020 to 2030 contributed to US$700.2 million in treatment and productivity losses. Additionally, quality-of-life losses in the range of 88 million to 871 million QALYs are also possible. If HSV-2 has contributed to the transmission of HIV, then in 2020, the PAF of HIV due to prevalent HSV-2 will be 32.8% (95% CI: 26.7% to 29.9%) and due to incident infections will be 4.2% (95% CI: 2.6% to 3.4%). The PAF due to prevalent infections will decline to 31.0% by 2030 and incident infections to 3.6%. Though we have accounted for the uncertainty in the epidemiological and economic parameter values via the sensitivity analysis, our estimates still undervalue losses due to limiting to the 15- to 49-year-old population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Economic losses due to genital herpes in LMICs can be large, especially when considering the lifelong nature of the disease. Quality-of-life losses outweigh spending on treatment and reductions in productivity. If HSV-2 has contributed to the spread of HIV in LMICs, then nearly one third of antiretroviral costs and HIV-related wage losses can be attributed to HSV-2. Given the magnitude of the combined losses, a vaccine against HSV-2 must be a global priority.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003938","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T13:46:11Z","timestamp":1671111971000},"page":"e1003938","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-3736","authenticated-orcid":true,"given":"Sachin","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-6657","authenticated-orcid":true,"given":"Houssein H.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-0843","authenticated-orcid":true,"given":"Christine","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-5983","authenticated-orcid":true,"given":"Rifat","family":"Atun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":true,"given":"Laith J.","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"issue":"5","key":"pmed.1003938.ref001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"C James","year":"2020","journal-title":"Bull World Health Organ"},{"key":"pmed.1003938.ref002","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"A Wald","year":"2007"},{"issue":"1","key":"pmed.1003938.ref003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clp.2014.10.005","article-title":"Neonatal Herpes Simplex Virus Infection","volume":"42","author":"SH James","year":"2015","journal-title":"Clin Perinatol"},{"issue":"1","key":"pmed.1003938.ref004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"EE Freeman","year":"2006","journal-title":"AIDS"},{"issue":"95","key":"pmed.1003938.ref005","doi-asserted-by":"crossref","first-page":"20140160","DOI":"10.1098\/rsif.2014.0160","article-title":"Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding","volume":"11","author":"JT Schiffer","year":"2014","journal-title":"J R Soc Interface"},{"issue":"8","key":"pmed.1003938.ref006","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/PSY.0000000000000374","article-title":"Association of Depressed Mood With Herpes Simplex Virus-2 Immunoglobulin-G Levels in Pregnancy","volume":"78","author":"PC Hsu","year":"2016","journal-title":"Psychosom Med"},{"issue":"1","key":"pmed.1003938.ref007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/1359105310367528","article-title":"The psychological impact of genital herpes stigma","volume":"16","author":"A Merin","year":"2011","journal-title":"J Health Psychol"},{"issue":"2","key":"pmed.1003938.ref008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","article-title":"Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data","volume":"20","author":"KJ Looker","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pmed.1003938.ref009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"K Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"3","key":"pmed.1003938.ref010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/sti.2007.027136","article-title":"Modelling the cost per ulcer treated of incorporating episodic treatment for HSV-2 into the syndromic algorithm for genital ulcer disease","volume":"84","author":"P Vickerman","year":"2008","journal-title":"Sex Transm Infect"},{"issue":"5","key":"pmed.1003938.ref011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/OLQ.0b013e31820b8bc8","article-title":"The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa","volume":"38","author":"P Vickerman","year":"2011","journal-title":"Sex Transm Dis"},{"key":"pmed.1003938.ref012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2334-1-5","article-title":"The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches","volume":"1","author":"TD Szucs","year":"2001","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pmed.1003938.ref013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/PSY.0b013e3181c5080a","article-title":"Recovery of immune control over herpes simplex virus type 1 in female victims of intimate partner violence","volume":"72","author":"S Sanchez-Lorente","year":"2010","journal-title":"Psychosom Med"},{"issue":"2","key":"pmed.1003938.ref014","doi-asserted-by":"crossref","first-page":"e55060","DOI":"10.1371\/journal.pone.0055060","article-title":"HIV-1 transmission within marriage in rural Uganda: a longitudinal study","volume":"8","author":"S Biraro","year":"2013","journal-title":"PLoS ONE"},{"key":"pmed.1003938.ref015","doi-asserted-by":"crossref","first-page":"100876","DOI":"10.1016\/j.eclinm.2021.100876","article-title":"Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions","volume":"35","author":"M Harfouche","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"pmed.1003938.ref016","first-page":"289","article-title":"Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions","volume":"79","author":"M Harfouche","year":"2019","journal-title":"J Inf Secur"},{"issue":"12","key":"pmed.1003938.ref017","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","article-title":"Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis","volume":"17","author":"KJ Looker","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"pmed.1003938.ref018","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/sextrans-2017-053336","article-title":"HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study","volume":"94","author":"R Omori","year":"2018","journal-title":"Sex Transm Infect"},{"issue":"9","key":"pmed.1003938.ref019","doi-asserted-by":"crossref","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","article-title":"Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study","volume":"8","author":"AB Hogan","year":"2020","journal-title":"Lancet Glob Health"},{"key":"pmed.1003938.ref020","unstructured":"GBD Results Tool | GHDx [Internet]. [cited 2017 Aug 1]. Available from: http:\/\/ghdx.healthdata.org\/gbd-results-tool."},{"issue":"1","key":"pmed.1003938.ref021","doi-asserted-by":"crossref","first-page":"e114989","DOI":"10.1371\/journal.pone.0114989","article-title":"Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012","volume":"10","author":"KJ Looker","year":"2015","journal-title":"PLoS ONE"},{"key":"pmed.1003938.ref022","article-title":"Analytic characterization of the herpes simplex virus type 2 epidemic in the United States, 1950\u20132050","author":"HH Ayoub","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"pmed.1003938.ref023","article-title":"Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses","volume":"8","author":"HH Ayoub","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"pmed.1003938.ref024","article-title":"The epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: systematic review, meta-analyses, and meta-regressions","author":"M Harfouche","year":"2021","journal-title":"medRxiv"},{"issue":"19","key":"pmed.1003938.ref025","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM199911043411904","article-title":"A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group","volume":"341","author":"AG Langenberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"pmed.1003938.ref026","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/0003-4819-121-11-199412010-00004","article-title":"Recurrence rates in genital herpes after symptomatic first-episode infection","volume":"121","author":"J Benedetti","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"pmed.1003938.ref027","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group","volume":"282","author":"L Corey","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"pmed.1003938.ref028","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1258\/0956462011923859","article-title":"Patients\u2019 perspectives on the burden of recurrent genital herpes","volume":"12","author":"R Patel","year":"2001","journal-title":"Int J STD AIDS"},{"key":"pmed.1003938.ref029","unstructured":"Price & Availability Data [Internet]. Health Action International. [cited 2020 Mar 19]. Available from: https:\/\/haiweb.org\/what-we-do\/price-availability-affordability\/price-availability-data\/."},{"key":"pmed.1003938.ref030","unstructured":"International Drug Price Indicator Guide\u2014s18714en.pdf [Internet]. [cited 2017 Aug 2]. Available from: http:\/\/apps.who.int\/medicinedocs\/documents\/s18714en\/s18714en.pdf."},{"key":"pmed.1003938.ref031","unstructured":"WHO | Global price tags [Internet]. WHO [cited 2017 Jun 16]. Available from: http:\/\/www.who.int\/choice\/globalpricetags\/en\/."},{"key":"pmed.1003938.ref032","article-title":"Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery","author":"K Stenberg","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"8","key":"pmed.1003938.ref033","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/OLQ.0b013e3181e212e5","article-title":"Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries","volume":"37","author":"C Corbell","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"Suppl 1","key":"pmed.1003938.ref034","first-page":"S166","article-title":"Drugs for STD management in developing countries: choice, procurement, cost, and financing","volume":"74","author":"F Van der Veen","year":"1998","journal-title":"Sex Transm Infect"},{"issue":"1","key":"pmed.1003938.ref035","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2468-2667(18)30213-5","article-title":"Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016","volume":"4","author":"MW Moses","year":"2019","journal-title":"Lancet Public Health"},{"key":"pmed.1003938.ref036","unstructured":"ILOSTAT\u2014the world\u2019s leading source on labour statistics [Internet]. [cited 2018 May 28]. Available from: http:\/\/www.ilo.org\/ilostat\/faces\/wcnav_defaultSelection;ILOSTATCOOKIE=Zn6oS2hA4g9ckMXyT3l2JTeORaorY-9iwKzOw5xWoemTpxGz2-Kg!125143199?_afrLoop=966594818050688&_afrWindowMode=0&_afrWindowId=null#!%40%40%3F_afrWindowId%3Dnull%26_afrLoop%3D966594818050688%26_afrWindowMode%3D0%26_adf.ctrl-state%3Dpqa11aqbo_4."},{"key":"pmed.1003938.ref037","unstructured":"World Bank Open Data | Data [Internet]. [cited 2020 Jul 28]. Available from: https:\/\/data.worldbank.org\/."},{"key":"pmed.1003938.ref038","unstructured":"World Population Prospects\u2014Population Division\u2014United Nations [Internet]. [cited 2019 Feb 17]. Available from: https:\/\/population.un.org\/wpp\/."},{"issue":"3","key":"pmed.1003938.ref039","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/sti.2004.011619","article-title":"Health related quality of life in genital herpes: a pilot comparison of measures","volume":"81","author":"DN Fisman","year":"2005","journal-title":"Sex Transm Infect"},{"issue":"1","key":"pmed.1003938.ref040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2202\/2152-2812.1009","article-title":"The Income Elasticity of the Value per Statistical Life: Transferring Estimates between High and Low Income Populations","volume":"2","author":"JK Hammitt","year":"2011","journal-title":"J Benefit-Cost Anal"},{"issue":"7","key":"pmed.1003938.ref041","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jech.55.7.508","article-title":"A heuristic approach to the formulas for population attributable fraction","volume":"55","author":"JA Hanley","year":"2001","journal-title":"J Epidemiol Community Health"},{"key":"pmed.1003938.ref042","unstructured":"UNAIDS\u2014KEY POPULATIONS ATLAS [Internet]. [cited 2018 Mar 4]. Available from: http:\/\/www.aidsinfoonline.org\/kpatlas\/#\/home."},{"issue":"5","key":"pmed.1003938.ref043","doi-asserted-by":"crossref","first-page":"e0154893","DOI":"10.1371\/journal.pone.0154893","article-title":"What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach","volume":"11","author":"J Stover","year":"2016","journal-title":"PLoS ONE"},{"key":"pmed.1003938.ref044","unstructured":"AIDSinfo | UNAIDS [Internet]. [cited 2019 May 12]. Available from: http:\/\/aidsinfo.unaids.org\/."},{"key":"pmed.1003938.ref045","unstructured":"Global AIDS Update 2016 [Internet]. [cited 2019 Jan 1]. Available from: http:\/\/www.unaids.org\/en\/resources\/documents\/2016\/Global-AIDS-update-2016."},{"key":"pmed.1003938.ref046","unstructured":"Global Health Expenditure Database [Internet]. Global Health Expenditure Database. [cited 2021 Feb 8]. Available from: https:\/\/apps.who.int\/nha\/database\/Home\/Index\/en."},{"key":"pmed.1003938.ref047","unstructured":"World Economic Outlook Database April 2015 [Internet]. [cited 2018 Dec 17]. Available from: https:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2015\/01\/weodata\/index.aspx."},{"issue":"3","key":"pmed.1003938.ref048","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40819-019-0658-3","article-title":"Uncertainty and Sensitivity Analysis Applied to an In-Host Malaria Model with Multiple Vaccine Antigens","volume":"5","author":"TO Orwa","year":"2019","journal-title":"Int J Appl Comput Math"},{"issue":"9","key":"pmed.1003938.ref049","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/00007435-199910000-00005","article-title":"Providing low-cost sexually transmitted diseases services in two semi-urban health centers in Central African Republic (CAR): characteristics of patients and patterns of health care-seeking behavior","volume":"26","author":"KA Parker","year":"1999","journal-title":"Sex Transm Dis"},{"issue":"8","key":"pmed.1003938.ref050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/sextrans-2014-051548","article-title":"Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey","volume":"90","author":"Q Abdool Karim","year":"2014","journal-title":"Sex Transm Infect"},{"issue":"15","key":"pmed.1003938.ref051","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/QAD.0000000000001584","article-title":"The effect of school attendance and school dropout on incident HIV and HSV-2 among young women in rural South Africa enrolled in HPTN 068","volume":"31","author":"MCD Stoner","year":"2017","journal-title":"AIDS"},{"issue":"9823","key":"pmed.1003938.ref052","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(11)61709-1","article-title":"Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial","volume":"379","author":"SJ Baird","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"pmed.1003938.ref053","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.socscimed.2009.02.035","article-title":"Is education the link between orphanhood and HIV\/HSV-2 risk among female adolescents in urban Zimbabwe?","volume":"68","author":"I Birdthistle","year":"2009","journal-title":"Soc Sci Med"},{"issue":"10","key":"pmed.1003938.ref054","doi-asserted-by":"crossref","first-page":"e25310","DOI":"10.1371\/journal.pone.0025310","article-title":"Economic Returns to Investment in AIDS Treatment in Low and Middle Income Countries","volume":"6","author":"S Resch","year":"2011","journal-title":"PLoS ONE"},{"key":"pmed.1003938.ref055","author":"M. Weaver","year":"2021","journal-title":"Unit cost of outpatient and inpatient visits from 1995 to 2040"},{"issue":"12","key":"pmed.1003938.ref056","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","article-title":"Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis","volume":"17","author":"KJ Looker","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"10132","key":"pmed.1003938.ref057","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(18)30698-6","article-title":"Spending on health and HIV\/AIDS: domestic health spending and development assistance in 188 countries, 1995\u20132015","volume":"391","author":"JL Dieleman","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"pmed.1003938.ref058","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/sti.2006.024117","article-title":"Sexual and treatment-seeking behaviour for sexually transmitted infection in long-distance transport workers of East Africa","volume":"83","author":"CN Morris","year":"2007","journal-title":"Sex Transm Infect"},{"key":"pmed.1003938.ref059","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/1471-2458-12-407","article-title":"Risk factors, healthcare-seeking and sexual behaviour among patients with genital ulcers in Zambia","volume":"12","author":"M Makasa","year":"2012","journal-title":"BMC Public Health"},{"issue":"14","key":"pmed.1003938.ref060","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0956462417727194","article-title":"European guidelines for the management of genital herpes","volume":"28","author":"R Patel","year":"2017","journal-title":"Int J STD AIDS"},{"key":"pmed.1003938.ref061","article-title":"Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development","author":"JT Schiffer","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"pmed.1003938.ref062","article-title":"Genital Herpes Has Played a More Important Role than Any Other Sexually Transmitted Infection in Driving HIV Prevalence in Africa","volume":"3","author":"LJ Abu-Raddad","year":"2008","journal-title":"PLoS ONE"},{"issue":"5","key":"pmed.1003938.ref063","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/infdis\/jit252","article-title":"Reactivation of Herpes Simplex Virus Type 2 After Initiation of Antiretroviral Therapy","volume":"208","author":"AAR Tobian","year":"2013","journal-title":"J Infect Dis"},{"issue":"4","key":"pmed.1003938.ref064","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/sti.79.4.280","article-title":"Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment","volume":"79","author":"J Melville","year":"2003","journal-title":"Sex Transm Infect"},{"issue":"11","key":"pmed.1003938.ref065","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/OLQ.0000000000000043","article-title":"Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years\u2014United States, 1988 to 2010","volume":"40","author":"RN Fanfair","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"1","key":"pmed.1003938.ref066","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/QAI.0000000000002743","article-title":"What Is the Burden of Heterosexually Acquired HIV Due to HSV-2? Global and Regional Model-Based Estimates of the Proportion and Number of HIV Infections Attributable to HSV-2 Infection","volume":"88","author":"R Silhol","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9717","key":"pmed.1003938.ref067","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(09)62038-9","article-title":"Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial","volume":"375","author":"JR Lingappa","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"pmed.1003938.ref068","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1006\/jeem.2001.1215","article-title":"A Review of WTA\/WTP Studies","volume":"44","author":"JK Horowitz","year":"2002","journal-title":"J Environ Econ Manage"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T13:46:47Z","timestamp":1671112007000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":68,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003938","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}